Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Henry

Showing results (71-80 of 139) with videos related to

Pageof 14
Sort By:
HIV Clinical Trials|July 3, 2015
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudineBenjamin Young, Kathleen E Squires, Karen Tashima, et al.
The Journal of Infectious Diseases|December 16, 2003
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley, Keith Henry, Christine Katlama, et al.
The Journal of Infectious Diseases|September 20, 2019
Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN StudyPragna Patel, Tim Bush, Lois Conley, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Plos One|October 20, 2012
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialJason V Baker, Kathleen Huppler Hullsiek, Rachel Prosser, et al.
Plos One|June 20, 2017
Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cellsRahul Sampath, Nathan W Cummins, Sekar Natesampillai, et al.
Biochemical Pharmacology|September 18, 2016
The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate effluxNatalie R Sealover, Bruce Felts, Charles P Kuntz, et al.
Biochemical Pharmacology|December 2, 2017
Corrigendum to "The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux" [Biochem. Pharmacol. 120 (2016) 46-55]Natalie R Sealover, Bruce Felts, Charles P Kuntz, et al.
Plos One|April 24, 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular riskPablo Tebas, William Keith Henry, Roy Matining, et al.
Sexually Transmitted Diseases|May 18, 2012
Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in carePragna Patel, Tim Bush, Kenneth Mayer, et al.
Pageof 14

Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
HIV Clinical Trials|July 3, 2015
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudineBenjamin Young, Kathleen E Squires, Karen Tashima, et al.
The Journal of Infectious Diseases|December 16, 2003
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley, Keith Henry, Christine Katlama, et al.
The Journal of Infectious Diseases|September 20, 2019
Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN StudyPragna Patel, Tim Bush, Lois Conley, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Plos One|October 20, 2012
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialJason V Baker, Kathleen Huppler Hullsiek, Rachel Prosser, et al.
Plos One|June 20, 2017
Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cellsRahul Sampath, Nathan W Cummins, Sekar Natesampillai, et al.
Biochemical Pharmacology|September 18, 2016
The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate effluxNatalie R Sealover, Bruce Felts, Charles P Kuntz, et al.
Biochemical Pharmacology|December 2, 2017
Corrigendum to "The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux" [Biochem. Pharmacol. 120 (2016) 46-55]Natalie R Sealover, Bruce Felts, Charles P Kuntz, et al.
Plos One|April 24, 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular riskPablo Tebas, William Keith Henry, Roy Matining, et al.
Sexually Transmitted Diseases|May 18, 2012
Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in carePragna Patel, Tim Bush, Kenneth Mayer, et al.
Pageof 14